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The prescribing information for sildenafil citrate (VIAGRA, Pfizer, New York, NY, USA) recommends
flexible dosing (50mg initially, adjusted to 100 or 25mg based on effectiveness and tolerability) in most
men with erectile dysfunction (ED). In many men, however, 100mg may be the most appropriate initial
dose because it would reduce the need for titration and could prevent discouragement and treatment
abandonment should 50mg be insufficient. Results of two previously published double-blind, placebo-
controlled sildenafil trials of similar design except for a fixed-dose vs flexible-dose regimen were
analyzed. Relative to the flexible-dose, approximately one-third more men were satisfied with an
initial and fixed dose of 100mg. In addition, tolerability was similar, and improvements from baseline
in outcomes on validated, ED-specific, patient-reported questionnaires were either similar (erectile
function and the percentage of completely hard and fully rigid erections) or greater (emotional well-
being and the overall sexual experience). The similarity in outcomes is not surprising given that
almost 90% of the men in the flexible-dose trial titrated to 100mg after 2 weeks. These data suggest
prescription of an initial dose of 100mg for men with ED, except in those for whom it is inappropriate.
International Journal of Impotence Research (2010) 22, 284–289; doi:10.1038/ijir.2010.17;
published online 1 July 2010
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Introduction
For most men with erectile dysfunction (ED), the
prescribing information for sildenafil citrate (VIAGRA,
Pfizer) recommends an initial dose of 50mg, increased
to 100mg or decreased to 25mg based on effectiveness
and tolerability (flexible dose).
1 However, 100mg silde-
nafil produced optimal erection hardness (fully hard
and rigid) in a substantial proportion of men with ED.
2
In addition, in dose-optimization studies
3,4 and at the
end of double-blind, placebo-controlled (DBPC) treat-
ment in recent reports of flexible-dose trials,
5,6 100mg
was the dose that was used by most men. Thus, the
100-mg dose may provide some additional benefit
beyond that achieved with the 50-mg dose and
may be the most appropriate choice for initiation
of therapy in many men.
This report assesses erection hardness, erectile
function, emotional well-being, satisfaction (disease
related and treatment related) and the overall sexual
experience in men treated with 100mg fixed-dose
sildenafil and in men treated with flexible-dose
sildenafil (50 and 100mg), using data from two
DBPC trials that were similarly designed except for a
fixed-dose vs flexible-dose regimen.
7,8 The objective
was to assess the efficacy and tolerability of an initial
dose of sildenafil 100mg relative to the flexible-dosage
regimen recommended in the prescribing information.
Materials and methods
One trial was a multinational (Republic of Korea,
Russian Federation, Spain and Sweden), parallel-
group, randomized (1:1:1) DBPC trial of fixed-dose
sildenafil (50 or 100mg) or placebo administered
on demand over an 8-week treatment period.
7 The
other trial was a multicenter (United States),
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www.nature.com/ijirparallel-group, randomized (1:1) DBPC trial of
flexible-dose sildenafil (50 or 100mg) administered
on demand over a 10-week treatment period.
8 In
both trials, p1 dose of study medication was to be
taken per day. Details of the patients and methods of
the two trials have been published previously.
7,8
As described previously,
7,8 several efficacy assess-
ments were conducted, including the Erection Hardness
Score (EHS
9), the International Index of Erectile
Function (IIEF),
10 the Self-Esteem And Relationship
(SEAR) questionnaire,
11–13 the Sexual Experience
Questionnaire (SEX-Q),
14 the Quality of Erection
Questionnaire,
15 the Erectile Dysfunction Inventory
of Treatment Satisfaction (EDITS)
16 and three global
efficacy assessment questions. Except for the global
efficacy assessment questions, all assessment tools
are validated, and a higher score indicates better
outcome. Safety data included all adverse events
(AE) reports from the original trials.
In this study, analyses were conducted on data
from the intent-to-treat population for each study,
which was defined as men who took at least one
dose of study medication and who provided suffi-
cient efficacy data for at least one efficacy analysis.
Treatment effects were estimated using least square
means from an analysis of covariance model for
change scores from baseline to DBPC end of treat-
ment on the IIEF, SEAR and SEX-Q, and the end-of-
treatment EDITS Index score. The model used terms
of baseline value, treatment group, investigator site
and prognostic factors (age, ED duration, ED etiol-
ogy) with P values calculated at the 5% significance
level for the test of treatment group differences.
Logistic regression (terms of treatment group, age,
ED duration and ED etiology) was used to analyze
the proportion of men who were satisfied with
treatment (dichotomized EDITS score). The percen-
tages of EHS 3, EHS 4 and EHS 3 or 4 erections based
on all of the event log data since the previous visit
were analyzed as clustered binomial data using a
logistic regression (terms for baseline percentage,
treatment group, age, ED duration and ED etiology),
with a scale adjustment for overdispersion (esti-
mated by Williams method) and model; treatment
effects were estimated using predicted percentages
from the model. Pearson correlations were com-
puted between the SEX-Q change from baseline
scores and all other outcomes (change from baseline
or end of treatment); 95% confidence intervals for
the correlation coefficient were constructed using
Fisher’s Z-transformation.
Results
Population and exposure
In both trials, each treatment group comprised B100
men, most of whom had ED that was of organic or
mixed etiology and that was mild to moderate in
severity (Table 1).
At week 2, 88% (92/104) of patients randomized
to flexible-dose sildenafil and 92% (97/105) rando-
mized to flexible-dose placebo increased their dose
Table 1 Baseline characteristics (intent-to-treat population)
Fixed dose Flexible dose
Placebo
(n¼95)
Sildenafil 50mg
(n¼94)
Sildenafil 100mg
(n¼99)
Placebo
(n¼105)
Sildenafil 50 and
100mg (n¼104)
Mean age±s.d. (years) 50±10 52±10 51±10 51±12 53±12
Race (%)
White 65 63 64 74 83
Black 0 0 0 13 8
Asian 35 37 35 0 2
Other 0 0 1 12 8
Mean ED duration (range) (years) 3.2 (o1–29) 3.2 (o1–26) 3.3 (o1–19) 3.8 (o1–13) 4.6 (o1–41)
ED etiology (%)
Mixed/organic/psychogenic 56/28/16 59/29/13 63/24/13 24/58/18 26/58/16
ED severity, (%) 16 27 14 28 33
Current comorbidities (%)
Hypertension 20 21 19 41 38
Hypercholesterolemia 7 7 2 21 24
Benign prostatic hyperplasia 9 15 12 17 16
Diabetes 8 9 13 17 15
Hyperlipidemia 6 7 2 10 9
Depression 1 2 1 9 10
Coronary artery disease 0 0 0 3 5
Abbreviation: ED, erectile dysfunction.
Fixed-dose vs flexible-dose sildenafil
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treatment, 87% (90/104) and 92% (97/105), respec-
tively, remained on the higher dose. During the
DBPC phase of each trial, patients in each treatment
group received an average of seven or eight doses
per month. Across both trials, only one man
discontinued sildenafil (flexible dose) because of
lack of efficacy and only two men discontinued
sildenafil because of treatment-related AEs: moder-
ate dyspepsia (100-mg fixed dose) and moderate
headache (100-mg flexible dose).
Efficacy
Sildenafil, whether initiated at a fixed dose of 50 or
100mg, or initiated at a dose of 50mg and titrated
as needed up to 100mg, was significantly more
effective than placebo (Table 2). The 100-mg fixed
dose was significantly more effective than the 50-mg
fixed dose in improving the IIEF Overall Satisfaction
domain score; the SEAR Sexual Relationship Satis-
faction domain, Overall Relationship Satisfaction
subscale and Total scores; all SEX-Q domain scores;
and the SEX-Q total score (Table 2). In addition, the
EDITS Index was significantly higher in the fixed-
dose sildenafil 100-mg group vs the fixed-dose
sildenafil 50-mg group, although the difference
between the dosage groups in the estimated percen-
tage of men who were satisfied with sildenafil
treatment (dichotomized EDITS scores: 93 vs 88%)
was not statistically significant (Table 2).
For the fixed-dose sildenafil 100-mg group rela-
tive to the flexible-dose sildenafil group (Table 2),
there was a similar improvement from baseline
in the percentage of EHS 4 erections (33 and 35%,
respectively), EHS 3 or 4 erections (36 and 35%,
respectively) and IIEF scores (p1 point difference
Table 2 Efficacy outcomes
Fixed dose Flexible dose
Placebo
(n¼95)
Sildenafil 50mg
(n¼94)
Sildenafil 100mg
(n¼99)
Placebo
(n¼105)
Sildenafil 50 and 100mg
(n¼104)
EHS occasions, % at baseline/estimated % with treatment
EHS 3 34/39 25/47 42/41 41/40 41/33
EHS 4 2/7 1/25* 2/35* 7/9 4/39*
EHS 3 or EHS 4 35/47 26/77* 45/81* 48/52 44/79*
LS mean change in IIEF domain score±s.e.
a
Erectile Function, range 1–30 2.1±0.7 7.7±0.7* 9.1±0.6* 2.2±0.9 8.0±0.9*
Intercourse Satisfaction, range 0–15 1.7±0.3 3.7±0.3* 4.3±0.3* 1.9±0.5 3.4±0.5**
Orgasmic Function, range 0–10 0.5±0.3 1.8±0.3*** 2.1±0.3* 0.3±0.4 1.8±0.4*
Overall Satisfaction, range 2–10 0.3±0.2 2.2±0.2* 3.0±0.2*
,**** 0.7±0.3 2.3±0.3*
Sexual Desire, range 2–10 0.3±0.2 0.9±0.2** 1.2±0.2* 0.4±0.2 0.8±0.2
LS mean change in SEAR score±s.e., range 0–100
a
Sexual Relationship Satisfaction 4.3±2.5 26.6±2.5* 34.4±2.4*
,**** 7.0±2.8 23.5±2.8*
Confidence 0.3±2.5 21.9±2.5* 27.9±2.5* 5.7±2.7 16.9±2.8***
Self-Esteem 1.3±2.6 23.4±2.6* 27.8±2.5* 7.6±2.9 19.5±2.9***
Overall Relationship Satisfaction –1.0±3.0 19.1±3.0* 28.0±2.9*
,**** 2.6±3.8 11.8±3.8**
Overall 2.5±2.4 24.7±2.4* 31.6±2.4*
,**** 6.4±2.6 20.8±2.6*
LS mean change in SEX-Q score±s.e., range 0–100
a
Erection domain 6.8±2.6 32.0±2.5* 39.4±2.5*
,**** 8.7±3.1 31.7±3.1*
Individual Satisfaction domain 4.5±2.4 22.9±2.3* 28.7±2.3*
,**** 7.0±2.7 21.7±2.7*
Couples Satisfaction domain 5.0±2.5 23.4±2.5* 30.8±2.5*
,**** 9.7±3.0 28.5±3.0*
Total score 5.8±2.4 27.6±2.3* 34.5±2.3*
,**** 8.6±2.7 28.5±2.8*
EDITS
LS mean Index±s.e., range 0–100 49.7±2.1 73.0±2.0* 78.4±2.0*
,**** 49.6±3.2 66.5±3.3*
Dichotomized, estimated % satisfied (odds
ratio vs placebo)
b
46 88 (8.7)* 93 (14.7)* 46 69 (2.6)***
Abbreviations: EDITS, Erectile Dysfunction Inventory of Treatment Satisfaction; EHS, Erection Hardness Score (EHS 3¼hard enough for
penetration but not completely hard; EHS 4¼completely hard and fully rigid); IIEF, International Index of Erectile Function; LS, least
squares; SEX-Q, Sexual Experience Questionnaire; SEAR, Self-Esteem And Relationship questionnaire.
aChange from baseline.
bDichotomized as satisfied (index 450) vs unsatisfied (index p50).
*Po0.0001 vs placebo.
**Po0.05 vs placebo.
***Po0.001 vs placebo.
****Po0.05 vs sildenafil 50mg.
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for the fixed-dose sildenafil 100-mg group relative to
the flexible-dose sildenafil group there was a greater
improvement from baseline in SEAR scores (8–16
point difference between the groups across SEAR
components) and in SEX-Q scores (3–7 point
difference between the groups across SEX-Q do-
mains), a greater least square mean±s.e. EDITS
Index (78.4±2.0 and 66.5±3.3, respectively), and
a larger estimated percentage of men who were
satisfied with sildenafil treatment (dichotomized
EDITS scores: 93 vs 69%). The SEX-Q total score,
which assesses the sexual experience overall in the
domains of erection, individual satisfaction and
couples satisfaction, correlated positively with all
other outcomes in both trials (Table 3).
Safety
In both trials, most AEs were mild or moderate in
severity. The most frequently reported AEs were
flushing, dyspepsia, headache and nasal congestion
in the fixed-dose trial, which occurred at similar
frequencies in the sildenafil 50-mg and 100-mg
groups, and flushing, headache, nasal congestion
and dizziness in the flexible-dose trial (Table 4).
No treatment-related serious or severe AEs were
reported in the sildenafil arms.
Discussion
As reported previously, sildenafil, whether initiated
at a fixed dose of 50 or 100mg,
7 or at a dose of 50mg
and titrated as needed up to 100mg,
8 was signifi-
cantly more effective than placebo in the treatment
of ED, and there were additional benefits to the
use of 100mg fixed-dose sildenafil compared with
50mg fixed-dose sildenafil.
8 Although definitive
statements about the comparative efficacy of 100-mg
Table 3 Correlations with the change in score from baseline on the SEX-Q total score
Pearson correlation coefficient (95% CI)
Fixed-dose sildenafil 50 or 100mg
vs placebo for 8 weeks
Flexible-dose sildenafil 50 and 100mg
vs placebo for 10 weeks
IIEF change in domain score
Erectile Function 0.80 (0.76–0.84)* 0.84 (0.80–0.88)*
Intercourse Satisfaction 0.72 (0.66–0.77)* 0.72 (0.65–0.78)*
Orgasmic Function 0.58 (0.49–0.65)* 0.57 (0.47–0.66)*
Overall Satisfaction 0.76 (0.70–0.80)* 0.77 (0.71–0.83)*
Sexual Desire 0.37 (0.27–0.47)* 0.54 (0.43–0.63)*
EDITS Index
a 0.85 (0.81–0.88)* 0.86 (0.82–0.89)*
EHS change in percentage occasions
EHS 3 0.20 (0.08–0.31)** 0.14 (0.00–0.28)
EHS 4 0.57 (0.48–0.65)* 0.68 (0.60–0.75)*
EHS 3 or EHS 4 0.70 (0.63–0.76)* 0.76 (0.69–0.82)*
SEAR change in component score
Sexual Relationship Satisfaction 0.87 (0.84–0.90)* 0.88 (0.84–0.91)*
Confidence 0.79 (0.74–0.83)* 0.60 (0.50–0.68)*
Self-Esteem 0.73 (0.67–0.78)* 0.55 (0.44–0.64)*
Overall Relationship Satisfaction 0.72 (0.66–0.77)* 0.48 (0.36–0.58)*
Overall 0.88 (0.84–0.90)* 0.83 (0.78–0.87)*
Abbreviations: EDITS, Erectile Dysfunction Inventory of Treatment Satisfaction; EHS, Erection Hardness Score; IIEF, International Index
of Erectile Function; SEAR, Self-Esteem And Relationship questionnaire; SEX-Q, Sexual Experience Questionnaire.
aEDITS Index outcome was from the end of treatment, whereas other outcomes were changes from baseline.
*Po0.0001.
**P¼0.001.
Table 4 Most frequently (42% of patients) reported all-causality
adverse events during the double-blind, placebo-controlled phase
of the trials
Fixed dose Flexible dose
Adverse
event, n
a
Placebo
(n¼95)
Sildenafil
50mg
(n¼94)
Sildenafil
100mg
(n¼99)
Placebo
(n¼105)
Sildenafil 50
and 100mg
(n¼104)
Flushing 0 5 5 2 16
Headache 3 1 3 6 14
Nasal
congestion
02 3 2 5
Dizziness 0 0 0 0 3
Dyspepsia 0 1 3 2 2
aAll events were of mild or moderate severity in the sildenafil groups.
Fixed-dose vs flexible-dose sildenafil
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regimen are limited by the fact that the regimens
were not compared within a controlled trial and the
protocols of the two trials collated herein were not
identical, the results of the current collated report
suggest that an initial dose of sildenafil 100mg is
at least as effective and well tolerated as an initial
dose of 50mg with the option to titrate as needed.
Definitive statements about the comparative toler-
ability of 100-mg fixed-dose sildenafil and the flexible-
dose sildenafil regimen are also limited by the collated
nature of the data presented in this report, although
the low rate of discontinuation because of treatment-
related AEs suggests that both regimens are generally
well tolerated. The results of the current report are
generalizable to the population of men with ED.
For the 100-mg fixed-dose regimen relative to the
flexible-dose regimen, there was a similar increase
from baseline in the percentage of EHS 4 erections
and EHS 3 or 4 erections, a similar improvement
from baseline in IIEF scores, a greater improvement
from baseline in SEAR scores and SEX-Q scores, and
a higher EDITS Index; approximately one-third more
men in the 100-mg fixed-dose vs the flexible-dose
regimen were satisfied with their sildenafil treat-
ment. The similarity in outcomes between the two
regimens is not surprising given that almost 90% of
the men who initiated treatment with flexible-dose
sildenafil titrated to a dose of 100mg after 2 weeks.
The apparent difference in outcomes on the SEAR,
SEX-Q and EDITS between the two regimens may
represent cultural differences between the European
and Asian population treated with 100mg fixed-
dose sildenafil and the US (mainly white) popula-
tion treated with flexible-dose sildenafil. The SEAR,
SEX-Q and EDITS assess health-related quality-
of-life concepts, which are likely to be more
susceptible to cultural differences than are more
functional concepts, such as those assessed by
the EHS and IIEF. Cultural differences on SEAR
responses were published previously.
13,17
Given that almost 90% of the men who initiated
treatment with flexible-dose sildenafil titrated to a
dose of 100mg after 2 weeks, initiating treatment with
100-mg sildenafil should greatly decrease the need for
dose titration and, in those men for whom a dose of
50mg might prove ineffective, may decrease the risk of
discouragement and treatment abandonment because
of inadequate dosing. The high proportion of men
titrating to a dose of 100mg supports earlier results,
which showed that 100-mg sildenafil produced optimal
erection hardness (fully hard and rigid) in a substantial
proportion of men with ED
2 and that 100mg was
the dose used by most men in dose-optimization
studies.
3,4,6 Several studies reported that titration to
the highest well-tolerated approved dose and/or early
dose optimization contributed to treatment success.
6
Treatment optimization, which includes selecting
the most appropriate dose, ‘ymay promote treat-
ment adherence and thus facilitate optimal patient
outcomes.’
6 Some patients who are prescribed
sildenafil for ED in the clinical practice setting
neither refill their initial prescription nor seek
alternative therapies.
18,19 For example, an analysis
of sildenafil use during the first 24 weeks of
availability at a large health maintenance organiza-
tion revealed that only 61% of patients filled a
second sildenafil prescription within 3 months of
their first prescription.
20 In addition, in a large dose-
optimization study in which sildenafil was initiated
at a dose of 50mg for 4 weeks according to the
package instructions, 14% (153/1109) failed to
return for the second visit for scheduled dosage
optimization.
6 In several studies, incorrect admin-
istration, including suboptimal dosing, was the most
frequent cause of nonresponse to sildenafil.
6
An initial dose of sildenafil 100mg may not be
appropriate in some men. For example, higher plasma
concentrations of sildenafil than those seen in healthy
young volunteers occurred in men aged 465 years, in
those who have hepatic impairment (for example,
cirrhosis) or severe renal impairment (for example,
creatinine clearance o30mlmin
 1) ,a n di nt h o s eu s i n g
concomitant potent cytochrome P450 3A4 inhibitors
(for example, ketoconazole, itraconazole, erythromycin,
saquinavir).
1,21–23 Because ritonavir greatly increased
the systemic level of sildenafil in a study of healthy
volunteers not infected with the human immuno-
deficiency virus, it is recommended not to exceed a
maximum single dose of 25mg of sildenafil in a 48-h
period.
1,23 In addition, men with left ventricular outflow
obstruction (for example, aortic stenosis, idiopathic
hypertrophic subaortic stenosis) and those with severely
impaired autonomic control of blood pressure can be
particularly sensitive to the actions of vasodilators,
including sildenafil.
1 When sildenafil is coadministered
with an a-blocker, patients should be stable on a-blocker
therapy before initiating sildenafil treatment, and
sildenafil should be initiated at the lowest dose.
1,24
In conclusion, sildenafil in doses of 50 and 100mg
is effective for the treatment of ED, and both doses
are generally well tolerated. An initial dose of
sildenafil 100mg appears to be at least as efficacious
and well tolerated as an initial dose of 50mg with
the option to titrate to the optimal dose. Further-
more, an initial dose of 100mg may reduce the need
for dose titration and may prevent discouragement
and treatment abandonment in men for whom a
dose of 50mg is insufficient. This suggests prescrip-
tion of an initial dose of 100mg, except in those for
whom it is inappropriate.
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